Vertex plans Phase 3 trial of cystic fibrosis treatment

Thu, 10/11/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) announced positive data from a Phase 2 trial of a second drug candidate, in addition to Kalydeco, aimed at treating cystic fibrosis. The company said it plans to start pivotal, or Phase 3, trials on VX-809 next year.

VX-809 was tested in combination with Kalydeco, or ivacaftor, a drug for which Vertex received approval earlier this year in both the U.S. and in Europe for treatment of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.